XJPX
4516
Market cap1.44bUSD
Oct 09, Last price
3,372.00JPY
1D
0.12%
1Q
-17.39%
Jan 2017
-41.46%
Name
Nippon Shinyaku Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Nippon Shinyaku Co., Ltd., an enterprise established in Kyoto, Japan, in 1911, engages globally in the production and distribution of pharmaceutical products and functional foods. Its reach extends across Japan, Switzerland, and various international markets, with operations structured into two core divisions: Pharmaceuticals and Functional Food. The Pharmaceutical division concentrates on a wide array of therapeutic areas, encompassing conditions affecting the urinary system, inflammatory and allergic responses, hematologic malignancies, cardiovascular and metabolic disorders, gastrointestinal issues, and other diverse diseases. Its extensive product catalog features notable treatments such as Zalutia, designed for urinary difficulties arising from benign prostatic hypertrophy; Eviprostat, also for prostatic hypertrophy; Bladderon for frequent urination; and Estracyt, targeting prostate cancer. For erectile dysfunction, it provides Cialis. In hematology and oncology, the company's portfolio includes Vidaza for myelodysplastic syndrome; Cylocide and CylocideN for solid tumors, acute leukemia, and malignant lymphoma; Gazyva, a humanized anti-CD20 monoclonal antibody; Defiterio for sinusoidal obstruction syndrome; and Trisenox and Amnolake for relapsed and refractory acute promyelocytic leukemia. Nippon Shinyaku also offers Uptravi, Adcirca, and Opsumit for the management of pulmonary arterial hypertension, alongside VILTEPSO for muscular dystrophy. Other specialized medications include Lunabel LD and Lunabel ULD for dysmenorrhea; Erizas, a dry powder inhaler for allergic rhinitis; Azunol Gargle liquid, an azulene-based gargling solution; Isobide for oral osmotic diuresis and Meniere's disease; Cephadol for vertigo; Livostin for allergic rhinitis and conjunctivitis; Regtect, aimed at maintaining alcohol abstinence; and Onetram and Tramal for the treatment of cancer and chronic pain. Furthermore, the company actively conducts research, development, and marketing efforts in the fields of gynecology, otorhinolaryngology, and orthopedics. The Functional Food segment broadens the company's offerings, supplying various health-focused ingredients, food preservatives, protein preparations, dietary supplements, and a selection of spices and condiments.
Key people
Manabu Beppu
Executive Officer, Senior Director of Research and Development Planning in Main Research and Development Unit · since 2025
Yoko Nakanishi
Executive Officer, Director of Human Resources · since 2025
Katsumi Noda
Executive Officer, Manager of Tokyo Office in Main Sales Unit · since 2023
Takeshi Seita
Executive Officer, Senior Director of Development in Main Research and Development Unit · since 2025
Yukiteru Sugiyama
Executive Officer, President of Subsidiary · since 2025
Hideyasu Takechi
Executive Officer, Director of Business Planning · since 2025
Yoshizumi Tanaka
Executive Officer, Senior Director of Reliability Assurance · since 2022
Masaya Toda
Executive Officer, Senior Director of License · since 2021
Hayato Wada
Executive Officer, Manager of Kansai Office in Main Sales Unit · since 2023
Toru Yamaguchi
Executive Officer, Manager of Odawara General Formulation Plant · since 2023
Kazuyuki Yamate
Executive Officer, Senior Director of DX · since 2022
Hitoshi Ishizawa
Manager of Functional Food Company, Director · since 2021
Takanori Edamitsu
Director · since 2018
Kazuyuki Iwata
Director · since 2025
Hitomi Kimura
Director · since 2021
Shigenobu Maekawa
Chairman of the Board, Representative Director · since 2021
Toru Nakai
President, Representative Director · since 2021
Yohtaro Hongo
Independent Director · since 2025
Yukari Kobayashi
Independent Director · since 2021
Mayumi Nishi
Independent Director · since 2023
IPO date
Jul 04, 1949
Employees
2,186
Domiciled in
JP
Incorporated in
JP
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑03 | 2025‑03 | 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | 2017‑03 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||